

# This Week's **Top** Industry News

Provided as a service to DCAT member companies each Friday.

**BUSY WEEK?** Here are the **TOP INDUSTRY NEWS** stories you might have missed, as selected by DCAT Editorial Director *Patricia Van Arnum*.

**1. [Merck KGaA Outlines Strategic Priorities for 2016](#)**

Merck KGaA held a 2015 Capital Market Day about the strategic priorities that will influence its operating result in 2016. The integration of Sigma-Aldrich as well as the further development of its pharmaceutical pipeline are at the top of the list. [Read More](#)

**2. [Pfizer, BioAtla Sign Potential \\$1 Billion Biologics Deal](#)**

Pfizer has entered into a license and option agreement with BioAtla LLC, a biotechnology company developing conditionally active biologic (CAB) antibody therapeutics, to advance antibody therapeutics based on BioAtla's CAB platform and using Pfizer's proprietary antibody drug conjugate payloads in a deal potentially valued up to \$1 billion. [Read More](#)

**3. [Roche Forms Two Immunotherapy Pacts Valued Up to \\$900 Million](#)**

Roche has formed two immunotherapy pacts valued up to \$900 million, one with Pieris Pharmaceuticals worth up to approximately \$416 million and one with SQZ Biotech potentially valued at more than \$500 million. [Read More](#)

**4. [Merck & Co., Samsung Bioepis Receive Korean OK for Biosimilar](#)**

Merck & Co. Inc. and Samsung Bioepis Co., Ltd. have received approval of Renflexis (infliximab), a biosimilar of the immunology medicine, Remicade, by the Ministry of Food and Drug Safety in Korea, marking a milestone in the companies' global biosimilars pact. [Read More](#)

**5. [EMA Accepts Sandoz's Biosimilar for Pfizer's Enbrel](#)**

The European Medicines Agency (EMA) has accepted the marketing authorization application for Sandoz's biosimilar to Pfizer's EU-licensed Enbrel (etanercept), a tumor necrosis factor alpha (TNF-alpha) inhibitor used to treat a range of autoimmune diseases, marking another key development in the company's biosimilars program. [Read More](#)

**6. [Baxalta Opens New R&D Center](#)**

Baxalta, the biopharmaceutical company spun off from Baxter earlier this year, has opened its Global Innovation Center in Cambridge, Massachusetts. The center will act as the innovation hub of the company's global infrastructure. [Read More](#)

**7. [AstraZeneca Develops App for Cancer Drugs](#)**

In a move to advance digital health solutions, AstraZeneca is partnering with Voluntas, a digital service provider, and the US National Cancer Institute to test and develop a smartphone app paired with a web portal to help clinicians and patients manage side effects associated with two AstraZeneca investigational candidates, cediranib and olaparib. [Read More](#)

**8. [Novo Nordisk Files for EMA Approval for Faster Acting Insulin](#)**

Novo Nordisk has submitted a marketing authorization application to the European Medicines Agency for the approval of faster-acting insulin aspart, a new formulation in which two new excipients have been added to ensure early and fast absorption. [Read More](#)

#### 9. [Lilly Ends Basal Insulin Peglispro Development Program](#)

Eli Lilly and Company said it will cease development of basal insulin peglispro, a potential treatment for Type 1 and Type 2 diabetes, in order to focus research and development efforts on other assets in its portfolio and pipeline. [Read More](#)

#### 10. [Daiichi Sankyo Plans to Close German Research Subsidiary](#)

Daiichi Sankyo plans to close its research subsidiary, U3 Pharma GmbH in Germany. U3, with about 40 employees, is engaged in R&D antibody targeting for cancer treatments. [Read More](#)

*The DCAT organization is happy to provide this service to its members each Friday.  
Have an enjoyable weekend!*

---

### About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691  
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599  
[www.dcat.org](http://www.dcat.org)

[Forward this email](#)



This email was sent to esanders@dcat.org by [dcatnews@dcat.org](mailto:dcatnews@dcat.org) | [Update Profile/Email Address](#) | Rapid removal with [SafeUnsubscribe™](#) | [About our service provider.](#)

Drug, Chemical, & Associated Technologies Association | One Union Street | Suite 208 | Robbinsville | NJ | 08691